Clinical Trial Update: Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating low-dose interleukin-2 in combination with rapamycin for Sjögren's syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)
• Rapamycin (sirolimus)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Sjögren's Syndrome | Phase 1, Phase 2 | Status: COMPLETED